ARTiDe
Aims to generate a breakthrough in antigen-specific cellular therapy for type 1 diabetes, and validate a generic production process for a future clinical trial.
ARTiDe has received funding from the European Union’s Horizon Europe Research and Innovation programme under grant agreement 101080823.
Autoantigen-specific Regulatory T cell therapy against Type 1 Diabetes (ARTiDe) will make a unique contribution to the understanding of autoimmunity in humans and the development of antigen-specific immunotherapy. ARTiDe has the ambition to take the lead in the restoration of long-lasting immune tolerance in Type 1 Diabetes (T1D) patients, aiming to provide a cure for this disease.
Context
Nearly
140.000
children suffer type 1 diabetes in Europe
+4%
of type 1 diabetes annual growth. Over 20.000 new cases per year in Europe
10%
of diabetes cases are type 1 diabetes
- Type 1 diabetes as Immune-mediated inflammatory diseases experience considerable morbidity and mortality.
- The pathology has no curative treatment
Focus
Regulatory T cells (Tregs) in immuno-therapeutic activities
Regulatory T cells (Tregs) are the central targets of immunotherapeutic activities.
They are the endogenous regulators of the immune system, with a unique power to inhibit unwanted immune responses.
Challenges in bringing autoreactive Tregs to patients
One of the main challenges to be overcome to bring autoreactive Tregs to patients is that there is no Good Manufacturing Practices (GMP) compliant process to produce T cell receptor (TCR)-engineered Tregs at the moment.
Objectives
ARTiDe is born from a real synergy between academic and industrial partners. Combining new technologies and expertise in a production process puts the project in a unique position to overcome all the challenges on the way to a successful TCR-engineered Treg product. ARTiDe ultimate goal is to set-up a GMP-compliant autoreactive Treg production process allowing to launch a phase I clinical trial.
To reach its goal, ARTiDe will:
Identify an optimal T Cell Receptor in Type 1 diabetic patients
Establish a validated GMP compliant production process
Deliver the clinical study protocol for the phase I trial
Latest tweets
Novel food innovations are crucial in the fight against diabetes. A new low glycaemic index rice variety from the Philippines could help reduce #type2diabetes in regions where #rice is a staple.
#HealthInnovation #DiabetesPrevention #SustainableFood
A great news from our project partner @PolTreg !
Some of the #type1diabetes (T1D) patients treated with PolTREG’s cellular #Treg #therapy could go without taking #insulin for up to two years.
For more details, click here:
https://www.linkedin.com/posts/poltreg-s-a_innodiasymposium-t1d-easd2024-activity-7238861932244463616-zyVF?utm_source=share&utm_medium=member_desktop
Join our team at @NeckerInem to work on a new #Immunotherapy for #type1diabetes! Don't hesitate to reach out if you have question!
Please #Repost
🚨We're hiring! Exciting opportunity for a Postdoc or PhD Fellow to join @FillatreauSimon's Lab at INEM!
Work on Microglia in Neuroinflammatory Disease and be part of groundbreaking research. 🔬
🔍Learn more and apply: https://www.institut-necker-enfants-malades.fr/index.php/offre-demploi/postdoctoral-or-phd-fellow-biology-microglia-neuroinflammatory-disease-fillatreau-lab